Shedding light on some peer-reviewed randomized control trials conducted so far with this anti viral drug touted for use in alleviating intensive care in severe COVID-19 patients.
On May 22, 2020 the New England Journal of Medicine published a preliminary report of a double-blind randomized, placebo-controlled trial of intravenous remdesivir.
They concluded that remdesivir is superior to placebo in shortening recovery time in adults hospitalized with COVID-19. A total of 1063 patients underwent randomization.
On April 29, 2020 the Lancet published a double-blind randomized, placebo-controlled multicentre trial of intravenous remdesivir.
237 patients were studied, in which no statistically significant clinical benefit was ascertained, however a numerical reduction in time to clinical improvement was observed in hospitialized COVID-19 patients.